IMPROVE. INNOVATE. TRANSFORM.
That is at the heart of what we do at Cipher.
We are a specialty pharmaceutical company that develops improved formulations of existing drugs. We search for products in defined markets to in-license into our pipeline. These products are based on currently marketed molecules paired with a novel drug delivery technology for enhanced performance. Our core competency is identifying these product opportunities and managing their clinical and regulatory development. Finally, we harvest the rewards by out-licensing to partners and generating royalty streams.
We have made strong progress since the Company was founded in 2000. With Lipofen®, we have IMPROVED the absorption profile of the popular cholesterol medication, fenofibrate. With our formulation of the increasingly prescribed pain medication tramadol, we have INNOVATED — creating an extended-release version that we believe has a best-in-class profile, offering rapid absorption and no food effect. And with our formulation of isotretinoin for the treatment of severe acne, we have developed a product that has a best-in-class profile and we expect it will be the first reformulation of its kind in the United States. The market opportunity for this product has the potential to TRANSFORM the future financial performance of the company.